Welcome to our dedicated page for Telomir Pharmaceuticals SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telomir Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telomir Pharmaceuticals's regulatory disclosures and financial reporting.
Telomir Pharmaceuticals, Inc. is the subject of an amended beneficial ownership report by John Paul DeJoria, acting both as trustee of the John Paul DeJoria Family Trust and in his individual capacity. He reports beneficial ownership of 3,554,871 shares of Telomir common stock. This represents 5.169% of the common stock, based on 68,774,956 shares outstanding as of August 13, 2026, as referenced from Telomir’s quarterly report. DeJoria has sole voting and dispositive power over all 3,554,871 shares and no shared voting or dispositive power.
Telomir Pharmaceuticals, Inc. reported a net loss of $1.7 million for the quarter and $2.7 million for the six months ended June 30, 2026, with no revenue as it remains a clinical-stage oncology company focused on its lead candidate Telomir-Zn. Cash was $5.2 million and stockholders’ equity $5.0 million, down from $7.3 million of cash and $5.9 million of equity at December 31, 2025.
Management discloses that these cash resources, combined with ongoing losses and expected spending, raise substantial doubt about the company’s ability to continue as a going concern over the 12 months following issuance, and additional external financing is needed to fund operations and clinical trials. Telomir completed a related-party merger with TELI Pharmaceuticals on April 22, 2026, issuing 34,389,710 shares of common stock to acquire worldwide intellectual property rights to Telomir-Zn; because the acquired net assets had a historical carrying value of zero apart from a $1.0 million cash contribution, the transaction generated a $46.1 million deemed dividend and roughly doubled shares outstanding to 68,774,956.
Operating expenses decreased sharply year over year, with general and administrative costs for the first half of 2026 falling to $1.9 million from $6.9 million, largely due to lower stock-based compensation, while research and development rose to $0.9 million as Telomir-Zn advanced. The company has FDA clearance of an Investigational New Drug application for a trial in advanced or metastatic triple-negative breast cancer and has a binding related-party funding commitment of up to $4.0 million tied to future Telomir-Zn regulatory and clinical milestones, alongside an unused $5.0 million related-party credit line.
Telomir Pharmaceuticals, Inc. reported that a peer-reviewed preclinical study of its lead candidate Telomir-Zn was published in the Journal of Oncology Research and Therapy, Volume 11, Issue 3. The study shows Telomir-Zn depletes intracellular iron to inhibit JmjC histone demethylases (KDMs), enzymes overexpressed in aggressive cancers, leading to tumor-suppressor gene reactivation and reduced tumor growth in prostate and triple-negative breast cancer (TNBC) models.
In TNBC models, Telomir-Zn reduced primary tumor size and significantly curtailed metastatic spread in an HCC1806 model, and showed synergistic tumor reduction when combined with paclitaxel in BT-549 xenografts, while one TNBC model (MDA-MB-231) did not respond. The compound killed iron-dependent TNBC cells at low concentrations while sparing normal cells at concentrations more than 50-fold higher, suggesting a favorable selectivity window. These findings support advancement of Telomir-Zn into a planned Phase 1/2 clinical trial in TNBC under an active IND.
Telomir Pharmaceuticals, Inc. is asking shareholders to vote at a virtual-only annual meeting on September 11, 2026, at 11:00 a.m. Eastern Time. Holders of 68,774,954 shares of common stock as of July 21, 2026 may vote; a quorum requires holders of 33.33% of outstanding shares present in person or by proxy.
Shareholders will vote on three items: electing four directors (including CEO and Chair Erez Aminov), ratifying Salberg & Company, P.A. as independent auditor for 2026, and approving a possible adjournment to solicit additional proxies. The Board recommends voting FOR all proposals. The proxy also details 2025 executive pay, with Mr. Aminov receiving total compensation of $4,880,350, a base salary increase to $500,000 effective January 1, 2026, and option repricing on 3,960,170 shares to an exercise price of $1.30. An equity incentive plan reserves 11,500,000 shares, and major holders include Brian McNulty at 26.93% and Mr. Aminov at 16.10% of common stock.
Telomir Pharmaceuticals director Whalen Matthew Pratt received a grant of 50,000 Non-Qualified Stock Options on April 16, 2026. The options have an exercise price of $1.3400 per share, expire on April 16, 2036, were granted under the 2023 Omnibus Incentive Plan, vested immediately, and leave him holding 50,000 derivative securities directly.
Telomir Pharmaceuticals, Inc. reported that director Edward Clouston MacPherson received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, vested immediately, expire on April 16, 2036, and represent 50,000 options held directly after the grant.
Telomir Pharmaceuticals, Inc. reported that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, equal to the closing price that day, and vested immediately upon issuance. They are exercisable for common stock and expire on April 16, 2036, resulting in Del Giudice holding 50,000 options after the grant, awarded under the company’s 2023 Omnibus Incentive Plan. The transaction was not made under a Rule 10b5-1 trading plan.
Telomir Pharmaceuticals filed an 8-K to share new preclinical data on its lead program, Telomir-Zn. A peer-reviewed paper in Biomedicine & Pharmacotherapy reports that Telomir-Zn improved glucose metabolism and insulin resistance in a diet-induced zebrafish model of Type 2 diabetes.
The study showed dose-dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin, and HOMA-IR, with HOMA-IR scores falling from about 10–12 to around 3 after 14 days of treatment. The company notes this is its second Telomir-Zn publication in 2026 and says the findings further support its metal-homeostasis mechanism, which also underpins its FDA-cleared Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.
Telomir Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Andriy Mushak. This Form 3 shows his status as an officer but does not list any common stock or derivative security transactions or holdings at the time of the filing.
Telomir Pharmaceuticals, Inc. reported a leadership change in its finance function. Effective June 6, 2026, Alan Weichselbaum will no longer serve as Chief Financial Officer, with the company stating his departure is not due to any disagreement over operations, policies, or practices. On June 3, 2026, the board appointed Andriy Mushak, a Massachusetts-licensed CPA with over 20 years of SEC reporting and audit experience, as fractional Chief Financial Officer. Mushak will provide services through LMAM Consulting Group, LLC under a consulting agreement, for which he will receive $6,000 per month. The company notes he has no disclosable related-party relationships or transactions with current executives or directors.